Experiment 69614

Worktypes

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismPhaseolus vulgaris (FABACEAE)
CitationUDANI,J: HARDY,M: MADSEN,DC:. (2004). BLOCKING CARBOHYDRATE ABSORPTION AND WEIGHT LOSS: A CLINICAL TRIAL USING PHASE 2 BRAND PROPRIETARY FRACTIONATED WHITE BEAN EXTRACT.. 9(1)
Amount utilized
Compound isolated
DiseaseSND A DECREASE IN TRIGLYCERIDES, ALTHOUGH STATISTICAL SIGNIFICANCE WAS NOT REACHED. AN AVERAGE OF 26.3 MG/DL, MORE THAN 3 TIMES GREATER A REDUCTION THAN OBSERVED IN THE PLACEBO GROUP (8.2 MG/DL) (P=0.07). NO ADVERSE EVENTS DURING THE STUDY WERE ATTRIBUTED TO THE STUDY MEDICATION. CLINICAL TRENDS WERE IDENTIFIED FOR WEIGHT LOSS AVERAGE OF3.79 LBS (AVERAGE OF .47 LBS PER WEEK) COMPARED WITH THE PLACEBO GROUP, WHICH LOST AN AVERAGE OF 1.65 LBS (AVERAGE OF 0.21 LB PER WEEK), RESPRESENTING A DIFFERENCE OF 129% (P=0.35). TRIGLYCERIDE LEVELS IN THE PHASE 2 GROUP WERE REDUCED OR AN IDENTICAL PLACEBO TWICE DAILY WITH MEALS. THE ACTIVE STUDY PERIOD WAS EIGHT WEEKS. 39 SUBJECTS COMPLETED THE INITIAL SCREENING PROCESS AND 27 SUBJECTS COMPLETED THE STUDY. THE RESULTS AFTER 8 WKS DEMONSTRATED THE PHASE 2 GROUP LOST AN 50 OBESE ADULTS WERE SCREENED TO PARTICIPATE IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFECTS OF TREATMENT WITH PHASE 2 VIRSUS PLACEBO ON WEIGHT LOSS. PARTICIPANTS WERE RANDOMIZED TO RECEIVE EITHER 1500 MG PHASE 2
Dose amount3.0 GM
Number1
Qualitative resultINACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
ExtractTYPE EXT NOT STATED
GenderGIVEN TO BOTH SEXES